🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
15/01/2020 10,23 10,58 10,19 10,36 +1,17% 3,81% 61.700
14/01/2020 9,90 10,48 9,90 10,24 +3,02% 5,86% 80.400
13/01/2020 10,01 10,23 9,74 9,94 -1,00% 4,90% 80.700
10/01/2020 10,28 10,35 9,94 10,04 -1,38% 3,99% 68.500
09/01/2020 10,09 10,29 9,94 10,18 +1,70% 3,52% 44.400
08/01/2020 9,78 10,28 9,58 10,01 +3,84% 7,17% 96.100
07/01/2020 9,45 9,87 9,05 9,64 +1,37% 8,68% 79.300
06/01/2020 9,59 9,83 9,46 9,51 -1,96% 3,91% 65.300
03/01/2020 9,63 9,91 9,37 9,70 -1,62% 5,61% 110.800
02/01/2020 10,10 10,14 9,59 9,86 -2,38% 5,45% 58.900
31/12/2019 9,84 10,18 9,84 10,10 +2,54% 3,50% 155.100
30/12/2019 10,72 10,74 9,71 9,85 -7,51% 9,61% 166.300
27/12/2019 10,95 10,96 10,55 10,65 -1,30% 3,78% 97.800
26/12/2019 10,25 10,88 10,17 10,79 +5,99% 6,93% 100.100
24/12/2019 9,92 10,27 9,80 10,18 +3,25% 4,74% 55.300
23/12/2019 9,53 10,05 9,20 9,86 +4,56% 8,92% 82.600
20/12/2019 8,82 9,49 8,72 9,43 +7,53% 8,73% 240.600
19/12/2019 8,36 8,82 8,30 8,77 +4,90% 6,22% 106.300
18/12/2019 8,50 8,60 8,26 8,36 +0,12% 3,96% 38.400
17/12/2019 8,65 8,65 8,19 8,35 -3,47% 5,32% 115.700
16/12/2019 8,72 8,90 8,59 8,65 +0,00% 3,52% 64.700
13/12/2019 8,92 9,11 8,56 8,65 -3,24% 6,17% 76.300
12/12/2019 8,80 9,06 8,73 8,94 +1,48% 3,75% 65.100
11/12/2019 8,59 8,94 8,51 8,81 +3,04% 5,05% 67.500
10/12/2019 8,19 8,69 8,18 8,55 +4,52% 6,23% 95.200
09/12/2019 8,21 8,40 8,12 8,18 -0,49% 3,41% 58.300
06/12/2019 7,89 8,39 7,69 8,22 +5,52% 8,87% 72.700
05/12/2019 7,94 7,98 7,73 7,79 -1,52% 3,15% 70.300
04/12/2019 8,32 8,42 7,75 7,91 -3,65% 8,05% 127.200
03/12/2019 7,84 8,23 7,82 8,21 +1,86% 5,23% 91.000